Focused on Nasopharyngeal Carcinoma, Perspectum Medical Showcases Multiple AI Products at RSNA 2018

From November 25 to 30, 2018, the 104th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) was grandly held at McCormick Place in Chicago, USA. Themed “TOMORROW’S RADIOLOGY TODAY,” the conference brought together experts and scholars from the global field of diagnostic imaging and radiology.

In addition to the presence of established leaders and emerging talents from both domestic and international radiology circles, the primary focus of this conference was on artificial intelligence (AI) and machine learning technologies. Top companies in the fields of AI and deep learning from more than 130 countries worldwide gathered here, with nearly 10,000 attendees visiting the Machine Learning exhibition area.

On the left is Dr. Xu Chenyang, Director and Partner at Baishi Medical,

On the right is Daniel Rueckert, Professor of Medical Image Analysis at Imperial College London.

Since 2018, discussions on artificial intelligence and machine learning have been incessant. The emergence of various AI companies, coupled with favorable policy support, has further accelerated the development of these two emerging technologies.

As a company with strong technical capabilities in the field of AI medical imaging, Guangzhou Baishi Medical Technology Co., Ltd. has been dedicated to the research and development of new industry technologies and algorithms, deeply implementing the philosophy of “Understanding Medical Needs, Expanding Imaging Horizons.” For its debut at the RSNA annual meeting, the core technical team showcased its full product lineup and engaged in in-depth exchanges with industry experts and exhibitor partners.

Previously, Dr. Lu Yao, President of Bosh Medical, led the team from the Joint Laboratory with Sun Yat-sen University to win the championship in the ISICM 2018 Pancreatic CT Segmentation Challenge, leveraging industry-leading algorithms and extensive clinical experience. This achievement is one of the outcomes since Bosh Medical and Sun Yat-sen University established their joint laboratory.

The Baishi team’s participation in RSNA aims not only to establish its developed products and algorithms as cornerstones for the advancement of the medical imaging and radiology industry, but also to contribute to the realization of the ultimate goals of healthcare.

So, what is the ultimate goal of healthcare? Baishi Medical believes it can be summarized in two words: “Health” and “Longevity.” But what is preventing us from achieving this goal?

Dr. Anko Nikolich-Žugich’s answer is cancer and aging. For this reason, anti-cancer and anti-aging interventions have become crucial approaches to extending lifespan, with new technologies undoubtedly serving as the means to achieve this goal.

The RSNA 2018 conference featured a distinct theme, “TOMORROW’S RADIOLOGY TODAY,” which directly highlighted artificial intelligence and machine learning. Although these two technologies once sparked controversy due to concerns that they would replace the jobs of current radiologists, Conference Chair Dr. Vijay M. Rao pointed out that they will not displace radiologists; rather, they will significantly enhance their work efficiency.

Dr. Rao also proposed two future scenarios for imaging work: the Diagnostic Data Hub and Total Imaging Care. These two scenarios will enhance physicians’ efficiency in assisted diagnosis and workflow services, while improving patients’ healthcare experience.

These two scenarios align closely with the products developed by Baishi Medical in clinical practice. Leveraging artificial intelligence and machine learning technologies, Baishi’s products can maximize the reduction of disease risk for patients with five types of cancer, including breast cancer and lung cancer, by assisting physicians in diagnosis.

The intelligent diagnostic products within the suite offer one-click, multi-disease diagnosis covering more than 94% of common pulmonary conditions, including pulmonary nodules, lung tumors, pneumonia, pulmonary tuberculosis, lung infections, and chronic obstructive pulmonary disease (COPD).

In addition, Baishi offers an automated radiotherapy target delineation product that covers applications such as automatic delineation of radiotherapy targets for nasopharyngeal carcinoma and automatic delineation of organs at risk in the head and neck region. While ensuring accuracy, it significantly reduces the time required for target delineation, greatly improving physicians’ efficiency and precision. The product has received widespread recognition from clinicians.

“Medical AI is an interdisciplinary field that requires the perseverance to endure long periods of obscurity. The industry is currently very hot, which has led to a certain degree of impetuousness; many products are akin to castles in the air, and entrepreneurs often lack a shared language with physicians,” said Dr. Lu Yao, Founder and President of Baishi Medical. He aims to apply his more than ten years of accumulated expertise in computer science and medicine to directly benefit patients, making tangible contributions.

“Doing things with integrity” is the belief that BoShi Medical has always adhered to, and this is precisely the essential condition needed to promote the development of the medical imaging and radiology industry, and even to achieve the ultimate goal of healthcare.